76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Becton Dickinson and Co
Closed
SectorHealthcare
175.19 0.01
Overview
Share price change
24h
Min
172.1
Max
177.65
Income | 27M 330M |
|---|---|
Sales | 104M 5.3B |
P/E Sector Avg | 33.915 56.602 |
EPS | 3.35 |
Dividend yield | 2.49 |
Profit margin | 6.259 |
Employees | 70,000 |
EBITDA | 93M 546M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +17.71% upside |
Dividend yield Sector Avg | 2.49% 2.45% |
|---|---|
Next Earnings | 7 Aug 2025 |
Next Dividend date | 30 Jun 2025 |
Next Ex Dividend date | 9 Jun 2025 |
Market Cap | -15B 50B |
|---|---|
Previous open | 175.18 |
Previous close | 175.19 |
News Sentiment
By Acuity
25%
75%
69 / 382 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Becton Dickinson and Co Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Becton Dickinson and Co Forecast
Price Target
By TipRanks
17.71% upside
12 Months Forecast
Average 206.4 USD 17.71%
High 261 USD
Low 172 USD
Based on 12 Wall Street analysts offering 12 month price targets forBecton Dickinson and Co - Dist in the last 3 months.
Sentiment
By Acuity
69 / 382 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Becton Dickinson and Co
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
